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Abstract
Background. Questions remain about the therapeutic durability of transoral incisionless fundoplication (TIF). In this
study, clinical outcomes were evaluated at 5 years post-TIF 2.0. Methods. A total of 63 chronic gastroesophageal reflux
disease (GERD) sufferers with troublesome symptoms refractory to proton pump inhibitor (PPI) therapy, absent or ≤2
cm hiatal hernia, and abnormal esophageal acid exposure were randomized to the TIF group or PPI group. Following
the 6-month evaluation, all patients in the PPI group elected for crossover to TIF; therefore, all 63 patients underwent
TIF 2.0 with EsophyX2 device. Primary outcome was elimination of daily troublesome regurgitation and atypical
symptoms at the 5-year follow-up. Secondary outcomes were improvement in symptom scores, PPI use, reoperations,
and patient health satisfaction. The cost-effectiveness of TIF 2.0 was also estimated. Results. Of 63 patients, 60 were
available at 1 year, 52 at 3 years, and 44 at 5 years for evaluation. Troublesome regurgitation was eliminated in 88%
of patients at 1 year, 90% at 3 years, and 86% at 5 years. Resolution of troublesome atypical symptoms was achieved
in 82% of patients at 1 year, 88% at 3 years, and 80% at 5 years. No serious adverse events occurred. There were 3
reoperations by the end of the 5-year follow-up. At the 5-year follow-up, 34% of patients were on daily PPI therapy
as compared with 100% of patients at screening. The total GERD Health-related quality-of-life score improved by
decreasing from 22.2 to 6.8 at 5 years (P < .001). Conclusion. In this patient population, the TIF 2.0 procedure provided
safe and sustained long-term elimination of troublesome GERD symptoms.
Keywords
transoral incisionless fundoplication (TIF), regurgitation, EsophyX, atypical GERD symptoms, proton pump inhibitor
(PPI), heartburn

Introduction
Following major changes in technique since the early
iterations of endoluminal fundoplication (ELF) and transoral incisionless fundoplication (TIF) 1.0 (gastrogastric
fundoplication), the TIF 2.0 procedure (esophagogastric
fundoplication) performed with the EsophyX2 device
(EndoGastric Solutions, Redmond, WA) has emerged as
a safe and effective therapy for chronic gastroesophageal
reflux disease (GERD) in patients with minimal anatomical deterioration of the gastroesophageal junction and
the diaphragmatic hiatus. Other studies have documented
the lack of serious adverse events (SAEs) and demonstrated the ability of TIF 2.0 to eliminate GERD symptoms,
heal reflux esophagitis, normalize or reduce pathological
distal esophageal acid exposure, and reduce proton pump
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inhibitor (PPI) use in a subset of chronic GERD
patients.1-5 Despite these successes, the durability of
these outcomes remained in question.
The TIF 2.0 EsophyX vs Medical PPI Open label
(TEMPO) trial is a multicenter, controlled, randomized
study with 3 prior publications.3-5 In these reports, the
superiority of the TIF 2.0 procedure compared with highdose PPIs in a select group of chronic GERD sufferers
with small or absent hiatal hernias was established. The
safety of the procedure, a very low incidence of associated postfundoplication side effects, and sustained positive outcomes up to 3 years post-TIF 2.0 have been
reported.3-5
The outstanding feature for the cohort of patients
included in this study is that they represented ideal surgical candidates for an antireflux procedure because of
their longstanding documented reflux, incomplete
response to optimized medical therapy, and willingness
to seek a surgical cure. Analysis of the 5-year follow-up
data offers the opportunity to assess the durability of
symptomatic control, quality-of-life outcomes, reoperation rates post-TIF, PPI use, and patient satisfaction. This
is the first study to assess long-term clinical outcomes
beyond 3 years in patients in the United States. The
authors expected that the determination of reoperation
rates 5 years post-TIF could offer preliminary cost comparisons for the TIF procedure versus the more traditional
laparoscopic Nissen fundoplication (LNF). Finally, we
hoped to use the results of this long-term follow-up to
propose a role for the TIF procedure in the antireflux
armamentarium for select patients.

Methods
Study Design
This was a randomized, multicenter, open-label study,
with a crossover arm, carried out at 7 community-based
practices in the United States. The study design has been
described in detail previously.3-5 Briefly, eligible patients
were randomly assigned to receive either TIF 2.0 or maximum dose PPI therapy with a target allocation ratio of
2:1. After their 6-month evaluation, all patients in the PPI
arm elected to undergo the TIF 2.0 procedure. Therefore,
for the purpose of this report, each patient served as his or
her own control as compared with the baseline assessment. The institutional review board of the participating
institutions approved the extension of the study, and written consent was obtained from all participants prior to the
5-year follow-up. The study was prospectively registered
and updated to reflect the study extension with the clinicaltrials.com (NCT01647958). The authors had access to
the study data, and the coauthors reviewed and approved
the final manuscript.
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Study Patients
All included patients were chronic GERD sufferers with
daily troublesome regurgitation and/or atypical symptoms refractory to PPI therapy, pathological esophageal
acid exposure confirmed by 48-hour pH monitoring off
PPI therapy (percentage time pH <4 greater than 5.3%),
and history of PPI use for at least 6 months.3 Patients with
hiatal hernia >2 cm, Hill grade III or IV, esophagitis of
grade C or D (Los Angeles classification), and Barrett’s
esophagus >2 cm were excluded from randomization.
Furthermore, patients with class 2 or 3 obesity (body
mass index [BMI] > 35 kg/m2), esophageal motility disorders, and previous gastric or esophageal surgery were
also excluded.

Study Procedures
Prerandomization patient characteristics, baseline
assessments, TIF procedure data, and follow-up evaluations up to 3 years postprocedure have been previously
reported.3-5 This included symptomatic assessment with
validated disease-specific questionnaires on and/or off
PPI therapy as well as esophagogastroduodenoscopy
and 48-hour pH-metry off PPIs at prespecified time
intervals.5 All patients in this study underwent the standard TIF 2.0 procedure using the EsophyX2 device
under general endotracheal anesthesia.5 The TIF 2.0
procedure created a full-thickness, partial gastroesophageal fundoplication secured above the Z-line with polypropylene “H” fasteners that were delivered through the
thickness of the apposed stomach and esophageal walls.
The length and circumference of newly built TIF
2.0 gastroesophageal valves was determined by performing an immediate postprocedure endoscopy and
using well-described standardized methods. The valve
length is measured as the distance in centimeters from
the apex of the fundus to the valve lip, as measured at
the incisors in endoscopic retroflexion.6 The valve circumference is defined as the distance in degrees
between the 2 most distant fasteners used to secure the
fundoplication.7 The count of contributing fasteners
was conducted during the immediate postprocedure
endoscopy.

Assessments and Follow-up
The TEMPO trial was initially designed to follow enrolled
patients for up to 3 years after TIF. After completion of
the 3-year follow-up, all investigators agreed to continue
following the patients for an additional 2 years. Data
were collected on elimination of troublesome symptoms,
PPI use, reoperation, adverse events, and patient
satisfaction.
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Troublesome symptoms were defined according to the
Montreal consensus definition as mild symptoms occurring 2 or more days a week, or moderate to severe symptoms occurring more than 1 day a week.8 In the TEMPO
trial, the Reflux Disease Questionnaire (RDQ) was used
to assess elimination of troublesome regurgitation.3-5
RDQ is a 12-item questionnaire that was designed to
assess the frequency and severity of heartburn (4 items
measuring the frequency and severity of pain and burning
behind the breastbone), regurgitation (4 items measuring
the frequency and severity of acid taste in the mouth and
movement of the material upward from the stomach), and
dyspeptic complaints (4 items measuring the frequency
and severity of pain or burning in the upper stomach).9
Response options range from 0 (not present) to 5 (daily)
for frequency and 0 (not present) to 5 (severe) for severity. Each patient’s score is calculated as the mean of item
responses, with higher scores indicating more frequent
and/or severe symptoms.
The Reflux Symptom Index (RSI) questionnaire was
used to assess elimination of atypical symptoms. RSI is a
9-item validated questionnaire used to measure atypical
GERD symptoms such as hoarseness, throat clearing,
excess throat mucus, dysphagia, and cough.10 The scale
for each individual item ranges from 0 (no problem) to 5
(severe problem), with a maximum total score of 45 and a
normality threshold of ≤13.
GERD Health-Related Quality of Life (GERD-HRQL)
was used to evaluate typical GERD symptoms, quality of
life, and patient satisfaction with their current health condition. A higher total GERD-HRQL score (range from 0
to 50) indicates more severe GERD.11
PPI use was self-reported by patients as complete cessation, occasional use (<3 d/wk), or daily use. Individual
investigators reported adverse events and reoperation
rates. Patient satisfaction with their current health condition was reported as part of the GERD-HRQL, with 3
possible answers: satisfied, neutral, or dissatisfied.
For the purpose of cost analysis, the Optum healthcare
database (data from 2011 to 2013) was used to determine
cost and resource utilization for TIF and LNF up to a
2-year follow-up. Standardized costs were computed for
inpatient and outpatient visits and medical therapy.

Primary End Points
Primary end points were elimination of troublesome
regurgitation and elimination of all troublesome atypical
symptoms at the 5-year follow-up as evaluated by the
RDQ and RSI, respectively.

Secondary End Points
Secondary end points were improvement in symptom
scores (RDQ, RSI, GERD-HRQL), PPI use, reoperations,

and satisfaction with current health condition. We also
compared the cost-effectiveness of TIF versus LNF based
on data obtained from the Optum group.

Data Collection and Statistical Analyses
An independent clinical research organization collected
the patient-reported outcomes and entered the data points
into the password-protected electronic database.
Postoperative data at 1-, 3-, and 5-year intervals were
compared with preoperative data using the repeatedmeasures analysis of variance (ANOVA) followed by the
post hoc Tukey-Kramer honestly significant difference
multiple comparison procedure. In general, continuous
variables were reported as means (SDs); categorical
variables were reported as percentage, counts, and 95%
CIs and were tested for significant difference using
McNemar’s test. All 3 TIF failures (patients who underwent a revisional procedure) were included in the analyses and were assigned the worst outcomes observed
during the study from the timing of revisional surgery
going forward. The statistical significance was prespecified by a P value of <.05.

Results
A total of 196 patients with chronic GERD were assessed
for study eligibility between June and August 2012. Of
these 196, 32% (63) met the study inclusion/exclusion
criteria and were randomized (40 patients into the TIF
group and 23 patients into the PPI group).3 The most
commonly cited cause for ineligibility was the absence of
pathological distal esophageal acid exposure (Figure 1).
Of the randomized patients, 70% (44/63) completed the
5-year follow- up assessments.

Patient Demographics and Baseline
Characteristics
The study population (n = 60) was 55% female (33) and
45% male (27%). The average age at the time of enrollment was 51.5 ± 10.3 years. The largest age segment was
the 50- to 65-year-old segment (52%, 31). Of the remaining patients, 40% (24) were younger than 50 years, and
only 8% (5) were older than 65 years. The average BMI
was 28.5 ± 3.7 kg/m2. GERD symptom duration was 11.2
± 9.8 years; PPI therapy duration was 8.6 ± 6.5 years.
Only 2% (1) of patients had the short-segment variant of
Barrett’s esophagus.

Safety and Procedure Data
No SAEs reported or any other complication associated with the TIF 2.0 procedure occurred in this study.3-5
As assessed by immediate postprocedure endoscopy,
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Figure 1. Study flowchart of treated and analyzed patients. Of the 85 patients not meeting eligibility criteria, 45% (38/85) had
normal pH test, 36% (31/85) had hiatal hernia >2 cm in axial length or greatest transverse dimension, 13% had Hill grade >II, 2%
had reflux esophagitis grade C or D (Los Angeles classification), 2% had body mass index >35 kg/m2, and 1% (1/85) had Barrett’s
esophagus >2 cm.5 Additionally, 32 patients declined to participate, and 16 were excluded for other reasons.3
Abbreviation: LNF, laparoscopic Nissen fundoplication.

TIF 2.0 created valves with an average length of 2.8 ±
0.5 cm and a circumference of 290° ± 20°. On average,
21 ± 4 fasteners were used to secure the newly created
valves.
Two revisional interventions were previously reported
(1 Dor fundoplication in the second year and 1 LNF in the
third year).5 Since that last report, 1 additional patient
underwent a reoperation (LNF). Therefore, the reoperation rate for this cohort was 5% (3/60). All surgical revisions were performed on patients with recurrent daily
troublesome GERD symptoms that persisted on PPI therapy. Endoscopic findings for the 3 patients undergoing
revisional surgery included recurrent hiatal hernia and
varying degrees of disruption of the TIF 2.0 valve. Before
revisional procedures, all patients had abnormal distal
esophageal acid exposure. At baseline, in addition to
daily troublesome regurgitation and/or atypical symptoms, all 3 patients suffered from daily troublesome
heartburn on twice-daily PPI therapy. Severity of GERD
in these patients was further confirmed by percentage

total time of pH <4 before the TIF 2.0 procedure (7.5,
16.8, and 19.5).

Primary Clinical End Point
Of 44 patients who underwent the 5-year follow-up, 98%
(43) suffered from troublesome regurgitation on PPI therapy at screening. At the 5-year follow-up, elimination of
troublesome regurgitation was achieved in 86% of
patients (37/43, 95% CI = 72%-94%). Similar findings
were observed at the 1- and 3-year follow-ups (Figure 2).
Elimination of troublesome atypical symptoms occurred
in 80% of patients at 5 years (31/39, 95% CI = 64%89%), 88% at 3 years (42/48, 95% CI = 75%-95%), and
82% at 1 year (45/55, 95% CI = 70%-90%). No statistically significant differences in elimination of troublesome regurgitation or atypical symptoms were found
between assessments at years 1, 3, and 5. Results are
reported regardless of PPI use at the time of assessment
(on or off PPI therapy).
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Figure 4. Reflux Index Score at screening and 1-, 3-, and
5-year follow-up assessments.
Figure 2. Elimination of troublesome regurgitation, as
assessed by the Reflux Disease Questionnaire at the 1-, 3-,
and 5-year follow-ups.

Figure 3. Regurgitation score, as assessed by the Reflux
Disease Questionnaire, at screening and the 1-, 3-, and 5-year
follow-ups.

Abbreviation: PPI, proton pump inhibitor.

Figure 5. Gastroesophageal Reflux Disease Health-Related
Quality of Life (GERD-HRQL) questionnaire, at screening and
1-, 3-, and 5-year follow-up assessments.

Abbreviation: PPI, proton pump inhibitor.

Secondary End Points
The total regurgitation score (assessed by RDQ) improved
significantly by falling from 3.0 on PPIs at screening to
0.7 at the 5-year follow-up (P < .001). There was no statistically significant difference between the total regurgitation scores at the 1-, 3-, and 5-year follow-up (Figure 3).
The total RDQ score improved significantly by decreasing
from 3.0 at screening to 0.8 at the 1-year, 0.6 at the 3-year,
and 0.7 at the 5-year follow-up (P <.001 in all cases vs
screening).
The total RSI score improved by decreasing from 22.2
at screening to 6.3 at the 5-year follow-up (P < .001).
There was no statistically significant difference between

the total RSI scores at 1-, 3-, and 5-year assessments
(Figure 4). The improvement in total GERD-HRQL score
was stable between the 1-, 3-, and 5-year follow-up
assessments (Figure 5).
All patients were on daily PPI therapy at screening. At
the 5-year follow-up, 34% (15/44, 95% CI = 22%-49%)
of patients were on daily PPI therapy. An additional 20%
(9/44, 95% CI = 11%-35%) of patients were taking PPI
medication occasionally. Therefore, complete cessation
of PPI therapy was achieved in 46% (20/44, 94% CI =
32%-60%) of patients who completed the 5-year followup (Figure 6).
Patient satisfaction with current health condition, as
assessed by GERD-HRQL, before treatment was 2%
(1/60, 95% CI = 0%-10%) and improved to 75% (45/60,
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Discussion

Figure 6. Percentage of patients on daily proton-pump
inhibitor (PPI) therapy at screening and 1-, 3-, and 5-year
follow-up assessments.

95% CI = 63% -84%) at 1 year, to 83% (43/52, 95% CI =
70%-91%) at the 3-year follow-up, and to 70% (31/44,
95% CI = 56%-82%) at 5 years (P <.001 vs screening in
all cases).
At 3 years post-TIF, all esophageal pH parameters,
with the exception of duration of longest reflux, improved
significantly as compared to baseline, with 40% (16/40)
of patients achieving pH normalization.5 Of the 24
patients with elevated levels of distal esophageal acid
exposure at 3 years (defined as percentage total time of
pH <4 greater than 5.3%, as measured by 48-hour pH
testing), 22% (5/24) were not available for the 5-year
follow-up. Of the remaining 19 patients, 63% (12/19,
95% CI = 41%-81%) reported complete cessation of PPI
therapy at 5 years; 16% (3/19, 95% CI = 5%-38%)
reported taking PPIs occasionally, and 21% (4/19, 95%
CI = 8%-44%) reported taking PPIs daily.

Cost Analysis
In the Optum database, 2734 LNF patients and 73 TIF
patients were available for the cost analysis. The average total cost over 2 years per LNF patient was $99 256,
as compared with $71 691 per individual TIF patient
(Table 1). The total average health care utilization for
LNF and TIF is shown in Figure 7.
In the subgroup of patients with resource utilization in
the top quartile (ie, most refractory PPI patients), the
average cost of care (preindex, first and second year postprocedure) summed over a 2-year period for a LNF
patient was $124 000, as compared with $66 000 for a
TIF patient.

The TEMPO trial is the first trial to assess the long-term
outcomes (5-year follow-up) of the TIF 2.0 procedure in
a US patient population. Patients suffering from troublesome regurgitation and atypical symptoms despite optimized acid-reducing therapy represent a common clinical
challenge. This validated the crossover randomized
design of this trial, allowing patients in the PPI arm to
undergo TIF 2.0 after their 6-month follow-up. Of note,
all of them chose this option, recognizing that the TIF 2.0
procedure may offer a valuable alternative.
The major contribution of this report is that it offers
conclusive evidence that the early benefits reported with
the TIF 2.0 procedure in previous shorter-term prospective multicenter randomized reports3-5 and prospective
multicenter observational studies12-14 are sustained at the
5-year follow-up. This is a milestone that has not been
achieved by previous GERD endoluminal therapies (eg,
EndoCinch, Enteryx, Gatekeeper, NDO Plicator, ELF,
and TIF 1.0), which, with the exception of the Stretta procedure, are no longer available because of safety concerns and/or lack of effectiveness. The quality and
durability of the long-term symptomatic outcomes
achieved in this study set apart the TIF 2.0 procedure
from these earlier GERD treatment modalities. These
results were achieved without unwanted SAE and postfundoplication side effects.5 Importantly, the elimination
of regurgitation, atypical symptoms, and heartburn, as
evaluated by validated, disease-specific questionnaires
(RDQ, RSI, GERD-HRQL), was maintained without significant deterioration over time. Therefore, this study
establishes the ability of the TIF 2.0 procedure to provide
long-term and durable resolution of troublesome GERD
symptoms, improvement of quality of life, and reduction
in PPI utilization in well-selected chronic GERD patients.
Our study design included patients who were selected
to demonstrate that the TIF 2.0 procedure would be beneficial for a subset of chronic GERD patients who failed
maximal medical therapy (hiatal hernia ≤2 cm, esophagitis Los Angeles grade A or B, Hill grade valve I or II).
These patients had been experiencing intractable symptoms and sought a minimally invasive surgical cure without side effects. The TIF 2.0 procedure has repeatedly
proven to avoid postfundoplication symptoms such as gas
bloat, flatulence, dysphagia, and diarrhea.5 The authors
reiterate that comparable results can only be achieved by
expert endoscopists with appropriate training in the standardized TIF 2.0 technique and by adhering to stringent
selection criteria similar to what was used in this study.
The reoperation rate in this report was determined to
be 5% (3/60) after 5 years, which is comparable to the
published rates of reoperation after LNF (3%-6%).15,16 In
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Table 1. Average Cost, With Breakdown by Category,
Associated With TIF 2.0 and LNF, as Accrued Over a
2-Year Follow-up Period (Data Obtained From the Optum
Database).

Office
Inpatient (hospital)
Emergency room
Outpatient (hospital)
Ambulatory surgical center
Independent laboratory
Pharmacy
Other
Total

TIF ($)

LNF ($)

7483
21 956
1162
23 837
3244
1384
11 136
1489
71 691

8474
44 652
961
23 540
2737
718
12 675
5500
99 256

Abbreviations: TIF, transoral incisionless fundoplication; LNF,
laparoscopic Nissen fundoplication.

Figure 7. The Optum database average utilization of health
care resources (number of claims) for laparoscopic Nissen
fundoplication (LNF) and transoral incisionless fundoplication
(TIF) over 2 years.

our study, 3 patients underwent Laparoscopic Nissen (2)
and Dor (1) fundoplication post-TIF without difficulty, as
was previously suggested by others.17 In contrast, studies
with earlier iterations of the device and techniques no
longer used (ELF and TIF 1.0) reported higher rate of
reoperations (11%-52%).18-20 Additionally, the higher
reported reoperation rates from the European studies can
be attributed to patient selection because patients with
large hiatal hernias (>2 cm), Hill grade valves III and IV,
and esophagitis C or D were often enrolled.
Limitations of the study include the relatively small
number of patients, which can be partially explained by
the challenges involved in enrolling patients with such
highly selective criteria. The study was, however, appropriately powered for statistical significance and had a
respectable follow-up rate of 70% at 5-year assessment.

We could also be criticized for not performing functional
tests and endoscopies at the 5-year mark, though they
were performed and reported in the 3-year follow-up.5
We note that a poor correlation between postintervention
GERD symptoms and physiological parameters has consistently been reported with all therapies, including traditional antireflux surgery,21,22 the TIF procedure,5,23 and
during PPI therapy (17% to 80% of patients demonstrated
abnormal esophageal acid exposure while being asymptomatic on PPI therapy).3,24-27 An additional potential
limitation of this study is that the results are reported
regardless of PPI use at the time of postprocedure assessment (on or off PPI therapy). We felt justified to use this
methodology because all patients in the study experienced daily troublesome regurgitation and/or atypical
symptoms on optimized PPI therapy before the TIF 2.0
procedure. Achieving control of troublesome symptoms
and improving quality of life with the use of PPIs after an
endoscopic antireflux procedure in patients whose symptoms were refractory to high-dose PPIs before intervention
should not necessarily be considered a treatment failure.4
In these cases, the TIF procedure may be viewed as a useful therapeutic adjunct to PPIs.
Although every patient enrolled in the TEMPO trial
experienced intractable GERD symptoms despite daily
PPIs (per inclusion criteria), more than two-thirds of
patients remained off daily PPIs 5 years after undergoing
the TIF procedure. Others have suggested that return to
PPI utilization is a poor indicator of recurrent GERD.28 In
our study, patients who were still on occasional or daily
PPIs had benefited from improved symptomatic control
after TIF 2.0, with 95% of patients enrolled not having
sought corrective surgery after 5 years.
The TIF 2.0 procedure appears to be cost-effective.
Medicare data suggest that the average reimbursement
for a TIF procedure ($4, 510.81) is about half the rate for
a LNF ($8, 573.99). A simulation applying these reimbursement rates to the 60 TEMPO patients (who were
candidates for either procedure) reveals a potential procedure-related savings of $238 543.40 for performing TIF
2.0 instead of LNF. Considering that the preprocedure
evaluation is the same for the TIF candidates and the LNF
candidates, and that the reoperation rate established in
this study for TIF is similar to that of LNF, we believe
that TIF may be a cost-effective alternative to LNF. In the
top quartile of medical resource utilization, such as in
GERD patient populations with similar characteristics as
our TEMPO patients, the potential savings may be even
more significant. Indeed, in that subgroup, the approximate total accrued cost reached $124 000 for a single
LNF patient versus $66 000 for TIF for the first 2 years
postprocedure. Out of the 63 patients enrolled in this
study and who underwent the TIF procedure, 5% had corrective surgery within 5 years, leaving 95% of patients
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who underwent a less-invasive procedure, with virtually
no side effects and at a significant overall cost savings
compared with more invasive GERD surgery.
Based on these results and the authors’ personal experience, and in an attempt to define the role of TIF in the
antireflux armamentarium, we suggest that in the appropriate patient population, the TIF 2.0 procedure could be
considered the definitive alternative therapy to PPIs in a
majority of patients undergoing the procedure. Indeed,
our study shows that at 5 years, a majority of patients had
enjoyed the combined benefits of not having undergone
any kind of additional corrective surgery, not being back
on daily dose of PPIs, experiencing complete resolution
of their troublesome symptoms, and being satisfied. In a
minority of patients, it appears that TIF 2.0 represented a
useful adjunct therapy to be used in conjunction with
various regimens of acid-reducing therapy. In this subgroup of patients, our study shows that the TIF procedure
helped eliminate or improve difficult-to-control symptoms such as regurgitation and atypical symptoms that
had been intractable and refractory to PPIs prior to the
procedure. Finally, in a very small group of patients, estimated at approximately 5% after 5 years, the procedure
would have represented a noninvasive first-line therapy
without “burning any bridges” or compromising the ability to perform additional surgery such as a LNF.15

Conclusions
Five years after undergoing TIF 2.0, the great majority
of TEMPO trial patients experienced durable elimination of all types of troublesome GERD manifestations,
including regurgitation and atypical symptoms. There
were no SAEs or any safety concerns associated with
the TIF 2.0 procedure. It also appears that in the appropriate patient population, the TIF 2.0 procedure could be
a cost-effective alternative to LNF.
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